O Amengual

Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Hydroxychloroquine: From Malaria to Autoimmunity

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

Guidelines on the investigation and management of antiphospholipid syndrome

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Systemic sclerosis: a prototypic multisystem fibrotic disorder

New approaches for managing antiphospholipid syndrome

Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS

Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease

Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.

Complement activation in patients with primary antiphospholipid syndrome

Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome.

Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation.